The Right Wine

and its

Health Implications



Trade Veteran

THE RIGHT WINE
AND ITS
HEALTH IMPLICATIONS

Author's Note

I came to wine from an unexpected direction. So did practically everyone else. Unlike a firefighter or a football player, one does not dream of becoming a "wine merchant." In June of 1976 I was the summer replacement for a graduate botany student. I was pursuing a career as a concert pianist at the time, experiencing just enough doubt to become open to other options.

Wine proved to be an extension of the musical studies; an immersion in culture — particularly European culture. In the 1970s wine retained all of its unique personality. The smells and tastes were airplane tickets in a bottle, transporting me to exotic and faraway places — in a sensual way that music offers in another dimension.

Ever curious, the faraway place that became my life was Spain, in its moment of reawakening after forty years of economic and political isolation. As a pioneering importer, the message to the world became "Spain is Europe and always has been." The cultural heritage was clear and present in its wines.

To great dismay, the critical press and technology combined to increasingly favor uniformity over cultural relevance. The scores drove the market, and it became harder and harder to locate those "airplane tickets." The uniformity also came at the cost of health, as the riper and more uniform wines were also less friendly to the human metabolism.

As importer, the wines we sold were those that we preferred to drink. As the point of reference increasingly became "100 Points" we began to refer to ourselves with pride as "The 88-Point Wine Company."

This essay could just as easily have focused upon culture rather than health. But in fact, they are the same thing.

This work was developed in collaboration with Claude (Anthropic).

Trade Veteran, April 2026

Abstract

The Right Wine and Its Health Implications is a unified analysis of the wine-health debate that brings together three essays originally published under the pen name Trade Veteran. Taken together, the work argues that a central question has gone unasked in four decades of research: whether the wine that dominates today's market is the same wine whose consumption produced the foundational health signal known as the French Paradox.

The book integrates three distinct modes of knowledge — each necessary, but insufficient alone. The policy-precaution register governs public health messaging and risk minimization, treating beverage categories as functionally equivalent for purposes of guidance. The epidemiological-scientific register, exemplified by the peer-review literature synthesized in Richard Baxter's *Wine and Health* (2019), establishes correlations, identifies biochemical mechanisms, and applies skeptical standards to claims of benefit and harm. The historical-biocultural register considers wine as a long-standing dietary practice shaped by climate, production method, and cultural context. The central claim of this work is that the question of wine and health can only be posed — and answered — by integrating all three.

Richard Baxter's *Wine and Health* is treated as a reliable and representative synthesis of the scientific field: unusually candid, careful, and critical of overstatement on all sides. Reading Baxter closely reveals that the literature has already established three key elements: (1) a consistent epidemiological association between moderate wine consumption and improved health outcomes; (2) a plausible and well-supported biochemical mechanism centered on grape polyphenols produced under vine stress; and (3) a documented transformation of the wine product over the past thirty years, characterized by rising alcohol levels and technological manipulation driven by critic-score optimization. What the literature has not done is connect these elements into the structural question they jointly imply.

That question — the "wrong product" hypothesis — asks whether the wine now dominant in the market delivers the mechanism that produced the observed health signal. The work argues that the absence of clinical studies explicitly stratified by production method, climate, and market era does not refute this hypothesis. Rather, it identifies the precise epistemic gap: the market transformation that displaced the historically health-relevant wine has also rendered the formation of a clean,

population-scale clinical cohort methodologically unattainable. The exposure capable of settling the question at scale no longer exists in sufficient concentration within contemporary retail systems.

Historical and pre-theoretical evidence — most notably Thomas Jefferson's documented wine-with-meals practice and the independently observed ulcer-healing effects of high-polyphenol wines later explained by *Helicobacter pylori* protein binding — are treated not as anecdotes, but as independent confirmations that align with the biochemical mechanism identified by modern science.

The practical implication is neither prohibition nor prescription. The book does not claim that wine is medicine, nor that public health guidance is misguided in intent. It concludes instead that the wine which produced the historical health signal remains available today — displaced but not extinct — and that the primary barrier to accessing it is informational rather than economic. *The Right Wine and Its Health Implications* offers a framework for distinguishing that product at a moment when the category "wine" no longer refers to a stable referent, and for understanding why the debate has remained unresolved despite the accumulation of evidence on all sides.

Table of Contents

— Author's Note

— Abstract

Part I — The Right Wine: Cool Climate, Ancient Roots — The Case for Quality and Health

1. The Historical Baseline
2. The Case for Cool-Climate Dry Wine
3. The Geography: Spain, Elevation, and the Latitude Illusion
4. The Paradox of Success: The Boom and Its Betrayal
5. Longevity, Blue Zones, and the French Paradox
6. The Medical Miscalculation
7. Conclusion: The Evidence of a Life

Part II — Epistemic Pluralism and the Wine-Health Debate

1. Three Registers, Three Governing Logics
2. The Category Drift Problem
3. The Living Counterexample

Part III — Wine & Health: An Epistemic Perspective

1. The Field as Baxter Represents It
2. What the Science Established and When
3. The Mechanism the Field Identified
4. The Template Legible to Technology
5. The Asymmetry Baxter Exemplifies
6. The Affordability Refutation
7. Pre-Theoretical Confirmation
8. The Color Question

Part IV — The Structural Conclusion

1. The Wrong Product Hypothesis
2. Why the Necessary Study Cannot Be Run
3. The Wine that Remains

— Coda: Wine as Food, Once and Still

Appendices

A. On the Charge of Anecdotalism
B. On Public Health Scalability

PART I

The Right Wine: Cool Climate, Ancient Roots — The Case for Quality and Health

---

1. The Historical Baseline

Georgia: The Ancient Reference Point

Archaeological evidence traces Georgian viticulture to approximately 6000 BCE, when inhabitants of the South Caucasus discovered that wild grape juice fermented naturally in shallow clay vessels buried through winter. Cultivated grape pips from that period have been found alongside the vessels used to ferment them. The Georgian word for wine, *ɣvino*, is considered a root borrowing from Proto-Indo-European — a measure of how thoroughly viticulture was woven into the culture that produced the language.

The vessel at the center of this tradition is the *qvevri* — an egg-shaped, beeswax-lined earthenware vessel with a pointed base and wide neck, buried underground and sealed during fermentation. This creates a reductive environment that addresses temperature control, oxidation prevention, and natural pressing simultaneously. The *qvevri* is distinct in shape and function from the clay amphorae used elsewhere in the ancient world. Georgia's claim is not that it used clay vessels — so did everyone — but that it developed a specific, sophisticated, underground fermentation technology with no equivalent in Mediterranean antiquity.

The winemaking process involves pressing the grapes and pouring the juice, skins, stalks, and pips together into the *qvevri*, which is then sealed and buried for five to six months of fermentation. The result — particularly for white varieties fermented on skins — is the category now internationally recognized as amber wine: structured, tannic, stable, and requiring no chemical intervention to achieve biological stability.

Georgia possesses nearly 400 indigenous grape varieties. The Alazani River Valley, framed against the Caucasus Mountains, combines well-drained mineral-

rich soils and high altitude — a profile far closer to the cool-climate, high-acid viticulture defended here than anything produced on Mediterranean shores in antiquity.

The continuity is what makes Georgia uniquely valuable as a reference point. Even during the Soviet era, when mass production degraded the official wine industry, many families continued small-scale winemaking using traditional techniques. Georgian producers today distinguish explicitly between *factory wine* and *local wine* — anything made in *qvevri* is considered local wine, a distinction that reflects not marketing language but genuine cultural memory. Georgia is the only major wine culture that can offer genuine historical and climatological equivalency with the wines described here, and the only legitimate ancient baseline for arguing what meal-integrated, additive-free, naturally fermented wine consumption looks like across a human lifetime.

Greco-Roman Wine: The False Ancestor

The invocation of ancient Greek and Roman wine consumption as a historical baseline for healthy drinking is not merely imprecise — it is a fundamental misunderstanding of the product. Mediterranean antiquity produced wines that were the opposite of what is defended here.

Greece and Rome were warm-climate Mediterranean producers. The taste in the time of Augustus was for strong, sweet wines: grapes were left to overripen to concentrate sugar for conversion to alcohol. Ripeness was not a problem to be managed — it was the baseline condition of Mediterranean viticulture.

Defrutum, *carenum*, and *sapa* were reductions of grape must, made by boiling down juice until reduced to two-thirds, one-half, or one-third of the original volume. A portion of this concentrate was then added back to the fermenting batch to raise its sugar content. These were not marginal practices — they were standard winemaking technology, documented exhaustively by Cato, Columella, Pliny, and Varro.

The adulterant tradition compounds the picture. Romans mixed their wines with honey, saltwater, herbs, spices, and resin lining the interior of storage amphorae. Greeks similarly added resin, herbs, seawater, brine, oil, and perfume — practices whose modern descendants include retsina, mulled wine, and vermouth.

The Roman addition of chalk to wine — ancestor of the plastering technique used historically in the Jerez region — was not adulteration but a response to a specific warm-climate chemistry problem. In low-acid musts, tartaric acid risks crystallizing out of solution; chalk binds and retains it. It is a relatively innocuous stabilizing technique, yet one entirely unnecessary with cool-climate, low-pH grapes. The distinction is precisely the point: warm-climate viticulture required systematic chemical intervention to achieve the stability that cool-climate grapes provide by nature.

The dilution practice, typically invoked as evidence of proto-healthy ancient consumption, requires reassessment. Ancient wines were stronger in both alcohol and flavor; dilution with water was a practical necessity. The starting point was concentrated, sweetened, frequently resinous wine of considerably higher potential alcohol than anything produced in cool-climate viticulture. The claim that dilution produced a beverage of 3-4% ABV has no documentary foundation.

Roman grape syrup was commonly boiled in lead pots, which sweetened the product through the leaching of lead acetate — a practice now understood to have caused chronic lead poisoning. A historically accurate batch produced in lead-lined vessels was found to contain lead at 29,000 parts per billion, nearly 3,000 times contemporary American drinking water limits. The ancestral Mediterranean wine tradition, taken in full, is a story of concentrated sugar, systematic adulteration, and inadvertent heavy metal poisoning. It is not the lineage this argument requires.

Georgia requires no such qualification.

---

2. The Case for Cool-Climate Dry Wine

The biochemical argument for cool-climate dry wine rests on two characteristics: low residual sugar and low pH.

Natural fermentation in cool-climate regions typically converts all grape sugar into alcohol. Dry wine — under 2g/L of residual sugar — carries no glycemic load and does not trigger the insulin response associated with mass-produced wines manipulated toward fruit-forward, glycerinated sweetness. The metabolic consequence is specific: when a high-sugar, high-alcohol wine is consumed, the

liver prioritizes processing the alcohol while the residual sugar triggers fat storage. The liver processing a glass of traditional Tempranillo from the Ribera del Duero plateau manages a single variable, not two competing ones.

The low-pH profile — typically 3.0 to 3.4 in high-acid cool-climate wines — mimics the acidic environment of the human stomach. Historically, this made wine the natural accompaniment to a carnivorous diet, aiding in the breakdown of fats and proteins and functioning as an internal disinfectant against foodborne pathogens. The human digestive system is adapted to process fermented acids as preservatives — a function distinct from the palate's detection of sugar as a rare, high-energy resource. Cool-climate wine engages the former mechanism; modern manipulated wine conflates both.

The mineral content of high-acid wine — specifically potassium, magnesium, and calcium in tartaric and malic acid solution — contributes to electrolyte balance in a way that high-alcohol, off-dry wines, which are net dehydrating, do not. The comparison to electrolyte-replacement drinks is not frivolous: both are acid-mineral solutions; the difference is the glycemic load and the context of consumption.

The ADH4 enzyme mutation, occurring approximately ten million years ago, allowed human ancestors to metabolize ethanol far more efficiently than earlier primate species — an adaptation to consuming naturally fermenting, overripe fruit on the forest floor. This mutation predates modern ethnic differentiation and is broadly shared across the populations relevant to the evidence presented here. It does not confer immunity from the consequences of high-speed, high-volume alcohol delivery; it confers metabolic integration with the low-level, slow-release ethanol of fermented food consumed with other nutrients.

Noble Varieties and the Millennium of Selection

The varieties that came to define the cool-climate canon — Pinot Noir, Riesling, Nebbiolo, Tempranillo — were not selected for yield or disease resistance. They were selected over centuries for their ability to ripen slowly in marginal climates such as Burgundy, Champagne, Piemonte, Mosel, and the elevated plateaus of northern Spain. Grapes that could not hold acidity through ripening produced wines that were biologically unstable, short-lived, and poor at table. Those

varieties did not survive selection. The ones that did are defined, at their core, by the quality prized here: the capacity to arrive at maturity with acidity intact.

This acidity is not incidental to wine quality — it is the mechanism of biological stability. A wine with sufficient natural acidity does not require the heavy sulfite additions or chemical stabilizers used to preserve modern, low-acid, high-pH wines. The noble variety tradition is, among other things, a millennium-long empirical demonstration that the wines worth aging, the wines that rewarded patience, and the wines that integrated most naturally with food were the same wines. Quality and health, in this tradition, were never in tension.

What distinguishes traditional cool-climate wine from its modern manipulated counterpart is the absence of the variables that tax this system: no added sugar, no acid adjustment, no concentrate, no glycerin, no reverse osmosis, no cultured yeasts selected for aromatic impact rather than clean fermentation. The wine that results is biologically stable without chemical assistance — stable because its acidity is sufficient, not because its sulfite levels are high.[1]

[1] For the biochemical mechanism Baxter documents in detail, including the stressed-vine / polyphenol-load relationship and its extensive health consequences, see Part III, Sections 3 and 4.

---

3. The Geography: Spain, Elevation, and the Latitude Illusion

The argument to this point has been general. The operative example is Spain — not because it is the only one, but because it is the one this argument knows from the inside.

Spain entered the 1990s boom with two distinct identities already in tension. The first was established and respected in the trade: the cool-climate, Atlantic-influenced tradition of elegant, structured, age-worthy wines from Rioja and the northern regions. The traditional bodegas of Rioja had been producing wines of Bordeaux-influenced structure and longevity for generations. These wines needed updating after the economic stagnation of much of the twentieth century — but they did not need reinvention. The stagnation, paradoxically, had served a

preservationist function: bodegas that lacked the ability to modernize also lacked the ability to restyle their wines for the scoring system.

The second identity was the danger: what those working in Spanish wine during the 1980s recognized as the two faces of Spain — a subcontinent with both Atlantic and Mediterranean exposures, offering a ready-made opportunity for the design and export of high-scoring, warm-climate wines of extraction. The Mediterranean and southern regions could produce, entirely authentically, the concentrated, ripe, high-alcohol wines that the emerging critical apparatus was beginning to reward. What authenticity could not always supply, additives could.

Glycerin — used clandestinely in Europe and more freely in the New World — adds weight and apparent sweetness to over-extracted wines, softening the palate astringency that high tannin and low acidity produce without further raising the ABV. The risk was that the scoring system would selectively reward the warm face while the cool face — already commercially fragile — lacked the infrastructure to compete for critical attention.

After Switzerland, Spain has the highest mean elevation of any country in Europe. The central plateau — the Meseta Central — sits at an average of approximately 2,500 feet (762 meters), and the premier wine regions occupy this plateau or rise above it. Ribera del Duero, often described as though it were a warm, flat river valley, lies on the elevated northern plateau at an average of 2,624 feet (800 meters). At these altitudes, summer temperatures can reach over 100ºF (40°C) during the day but fall by as much as 45ºF (25°C) at night — a diurnal range that preserves acidity and structural tension in ways that latitude figures alone entirely misrepresent.

Rioja and Ribera del Duero sit at approximately the same latitude as southern Oregon — north, in large part, of the Napa and Sonoma benchmarks that defined the scoring system's aesthetic preferences. The perception of Spain as categorically warmer than France or Germany is a commercial artifact.

Microclimate is the operative concept throughout. In the best Ribera del Duero wines, daytime sun provides ripe dark fruit and power while the nighttime cool preserves the acidity that brings freshness and structural tension. The same dynamic operates in Rioja's most westerly extreme, in the high-altitude expressions of lesser-known regions, and — as the Blue Zone evidence demonstrates — in the

mountainous interior of Sardinia, where the elevation-influenced Cannonau produces wines of significantly higher polyphenol concentration and greater structure than the valley-floor expressions of the same variety. In each case, it is the cool-microclimate version of a warm-climate region's wine that most closely approximates the profile defended here.

This distinction was legible to anyone paying attention to terroir rather than scores. It was the north star that guided a small number of importers through the commercial turbulence that followed.

---

4. The Paradox of Success: The Boom and Its Betrayal

On November 17, 1991, Morley Safer's thirteen-minute segment on *60 Minutes* — viewed by an estimated 33 million people — introduced the French Paradox to mass American consciousness. Research by French epidemiologist Serge Renaud, who studied cardiovascular disease in southwest France, had provided the scientific basis for the broadcast. The observation was genuine: populations in southwestern France, consuming a diet rich in saturated fat alongside regular, moderate red wine integrated into meals, showed cardiovascular disease rates dramatically lower than comparable American populations. Red wine sales in the United States rose 39% in 1992 and maintained that elevated level in subsequent years.

The wine culture the broadcast was actually observing — the Gascon peasantry of Madiran country, the farmers of the Languedoc, communities with centuries of meal-integrated consumption of tannic, high-acid, traditionally made wine — was not the culture that responded to it. The broadcast reached a mass American market that proceeded to purchase the red wines most available to them.

The 100-point scoring system had been systematically rewarding extraction, concentration, ripeness, and fruit-forward generosity since the early 1980s. In a single issue from June 1986, the wine representing one of the most celebrated discoveries in Spanish viticulture received 90 points, while a heavier, more extracted wine from a warmer district — a region historically known for dark, alcoholic, rustic production — scored higher. The framework was evaluating

impact and concentration: the immediate sensory impression that high extraction and residual sugar produce on an isolated palate.

The market lag gave a brief window of survival to importers operating on different criteria. From roughly 1987 to the mid-1990s, the critical apparatus had already corrupted the evaluative standard, but commercially-minded importers had not yet fully followed. When the mid-1990s boom fully arrived — driven by the French Paradox's health halo, a booming American economy, and the cult wine phenomenon — the market moved decisively toward the style the scoring system rewarded.

Many Spanish regions played toward the globalised market during this period: heavily oaked, ultra-ripe, extracted — show wines rather than drinking wines. The same pressure operated across France, Italy, and the New World. The French Paradox had given wine a health halo; the market delivered a product that bore no resemblance to the wine the Paradox had observed.[2]

In the same year as the broadcast, France passed the Evin Law — broad public health legislation restricting alcohol advertising on television, in film, and in print. Its motivations were general rather than directed at wine specifically. But the timing carries a quiet irony: in the very year that America embraced red wine as medicine, France was legally circumscribing how alcohol could be presented to its own public.

The boom did not deliver the Gascon farmer's Madiran. It delivered critical scores, cult wines, and a Spanish wine industry under intense commercial pressure to abandon the terroir-driven, high-acid, low-manipulation model its best producers had maintained for generations. The medical community, observing the health outcomes of populations consuming this product at elevated volumes and without the meal-integration context the French Paradox had described, built its subsequent case against wine as a category. The indictment was accurate for the product it examined. It was a category error for the product defended here.

[2] For independent scientific documentation of the alcohol escalation this transformation produced, including the UC Davis / Journal of Wine Economics 2015 study, see Part III, Section 2.

5. Longevity, Blue Zones, and the French Paradox

The Pre-Industrial Caveat

Any attempt to draw longevity evidence from European wine-drinking populations prior to the Industrial Revolution founders on distorting variables too severe to work around. The Black Death eliminated roughly a third of Europe's population in the 14th century alone; feudal nutrition and labor conditions suppressed baseline health across subsequent centuries; endemic warfare created mortality patterns entirely disconnected from dietary habit. The pre-industrial European record is acknowledged here and set aside.

The Blue Zones

Beginning in 2004, Dan Buettner and a team of demographers, scientists, and anthropologists identified five places around the world where people consistently live past 100 — the Blue Zones — at ten times the rate of the United States average. Two of the five are Mediterranean wine cultures directly relevant to the argument: Sardinia, Italy, and Ikaria, Greece.

Sardinia is home to the world's longest-lived men — an anomaly worth noting, since in most populations women outlive men by approximately five to one. The Sardinian longevity is concentrated in mountainous interior communities of shepherds whose lifestyle involves daily physical labor, a largely plant-based diet, and regular, moderate wine consumption integrated into meals and social ritual. The centenarians among them drink Cannonau — a red wine containing two to three times the flavonoid levels of most other wines, including a specific procyanidin shown to help maintain vascular elasticity.

Cannonau is the Sardinian expression of Grenache. The key variables are altitude and microclimate: the higher-altitude, interior expressions of the variety produce wines of significantly greater polyphenol concentration, bolstered acidity, and structural tension than the valley-floor versions.

The Blue Zone research does not claim wine alone explains Sardinian longevity. The picture is one of integrated factors: movement, diet, community, stress management, and wine as one component of a coherent daily structure. What the research establishes is that moderate drinkers in Sardinia and Ikaria were predicted

to be protected from cardiovascular disease — and that this protection operated within a population consuming traditional, minimally manipulated wine with meals, not in isolation.

The French Paradox and Its Unintended Consequences

The populations Renaud studied — French farmers and working people in the southwest, communities with centuries of meal-integrated consumption of tannic, high-acid, traditionally made wine — were not the consumers who responded to Safer's broadcast. The broadcast reached a mass American audience that proceeded to purchase the red wines most available to them: the fruit-forward, high-extraction, increasingly high-residual-sugar products that the market, already moving in that direction under the influence of the scoring system, was primed to deliver.

The French Paradox identified something real. The boom it triggered delivered something else entirely.

---

6. The Medical Miscalculation

The contemporary medical consensus on alcohol and health is not without foundation. Heavy and binge drinking cause documented harm — to the liver, cardiovascular system, and through multiple cancer pathways — and no serious argument contests this. The argument here does not propose to rehabilitate alcohol as a category. It proposes something more specific: that the epidemiological data underlying the broadest anti-alcohol conclusions was gathered from populations consuming a product bearing little resemblance to the wines described here, under conditions of consumption that the ancestral model explicitly rejected.

The WHO's January 2023 statement clarified that available evidence cannot indicate a threshold at which the carcinogenic effects of alcohol switch on, and that no studies demonstrate that the potential benefits of light and moderate drinking on cardiovascular disease and type 2 diabetes outweigh the cancer risk at those same levels. The statement applies to ethanol as a chemical compound regardless of its vehicle. It does not distinguish between a 15.5% Napa Cabernet with measurable residual sugar consumed without food and a 12% high-acid, zero-residual-sugar

Tempranillo consumed over two hours with a meal. From an epidemiological standpoint — which is where the policy conclusions originate — that failure to distinguish is a significant methodological gap.[3]

Over 70% of global systematic reviews examining alcohol and mortality published over the past 30 years did not exclude former drinkers from the comparison group — the so-called sick-quitter effect. Some people in the abstainer control group are former drinkers who gave up alcohol because of existing health problems, meaning that comparing current drinkers to a control group containing less-healthy former drinkers makes moderate drinkers appear healthier than they are, and compromises the baseline against which harm is measured.

The evidence base for a significant association between light drinking — defined as ten grams of alcohol or less per day — and cancer risk is fraught with weak associations and significant methodological issues, including study heterogeneity and the understudied role of different drinking patterns. The studies do not differentiate by product type or consumption context.

A cardiologist at the University of California San Francisco, speaking in 2024, described the evidence for health and harm from moderate alcohol consumption as fairly equal — not the settled science the WHO statement implies. A 2023 JAMA Network review frequently cited in anti-alcohol coverage does not show statistically significant harm from moderate drinking, and concludes that higher mortality risk begins for women at 1.8 drinks per day and for men at 3.2 drinks per day — quantities that exceed the French, UK, and US guidelines.

This argument does not claim that wine is medicine. Its claim is more precise: that the medical case against wine as a category was built on data drawn overwhelmingly from the wrong product, consumed in the wrong way, by populations whose drinking habits were shaped by the commercial transformation documented here. The Gascon farmer drinking his Madiran with dinner, the Sardinian shepherd with his daily Cannonau, the Georgian winemaker opening a *qvevri* at harvest — these are not the populations whose outcomes appear in the longitudinal studies. The populations that do appear in those studies were, by the 1990s and 2000s, consuming wine in the context created by the boom: higher alcohol, higher residual sugar, more frequent consumption without food, selected by marketing and point score rather than by terroir, acidity, and digestive function.

The medical community identified a real problem in that population. Its error was categorical — indicting the vessel rather than what had been put into it.

[3] Baxter's synthesis confirms the product-substitution problem from within the scientific literature; see Part III, Section 2.

---

7. Conclusion: The Evidence of a Life

The argument, stated plainly: the medical community's categorical case against wine was constructed from data gathered from the wrong product, consumed in the wrong manner, by populations whose drinking habits were shaped by a commercial transformation that systematically displaced the ancestral model the case claimed to be evaluating. The French Paradox identified something real in 1991. The boom it triggered delivered something else entirely. The science that followed measured the consequences of that something else while treating them as evidence about wine as a whole.

The ancestral model defended here is not an abstraction. It has geographical coordinates — the Caucasus, the mountainous interior of Sardinia, the harsh plateaus of northern Spain, the Atlantic-facing hillsides of Galicia, the river valleys of Burgundy, Bordeaux, Piemonte, Champagne and the Rhine. It has a chemistry — low residual sugar, low pH, minimal intervention, biological stability achieved through acidity rather than additive. It has a context — the meal, the table, the rhythm of a working day, wine as digestive accompaniment rather than recreational vehicle. And it has a history — not the false history of Greco-Roman antiquity this argument corrects, but the genuinely ancient, unbroken, archaeologically documented tradition of the Caucasus, and the medieval northward migration through which the noble varieties of cool-climate Europe were selected, over centuries, for precisely the qualities at the center of this argument.

The longevity evidence from Sardinia and Ikaria does not prove that wine extends life. It demonstrates something more durable: that populations consuming traditional, minimally manipulated wine as one integrated component of a coherent daily structure — movement, meals, community, purpose — reach extreme old age

at rates anomalous by global standards, and that the wine these populations drink shares the chemical profile described throughout.

The methodological problems within the anti-alcohol research literature are real and documented. The sick-quitter effect has compromised the baseline of over seventy percent of the major longitudinal studies. The failure to distinguish between product types, consumption contexts, and drinking patterns has produced category-level conclusions from data that was never category-representative.

Documented population-level differences in alcohol metabolism exist — enzyme variants affecting ethanol and acetaldehyde processing are real, and their consequences for individuals carrying certain variants are physiologically significant. But the ADH4 mutation conferring efficient ethanol metabolism, established approximately ten million years ago, predates modern ethnic differentiation and is broadly shared across the populations most relevant to the evidence here. The convergence of longevity outcomes across genetically distinct populations in Georgia, Sardinia, and Ikaria points toward behavioral and product variables as the primary operative factors. The wine matters. The manner of drinking matters. The meal matters. Ancestry is a secondary variable against these primary ones.

What the epidemiological literature cannot produce, and what is offered here instead, is longitudinal biographical evidence of a specific kind. A career spanning five decades was built on a single organizing principle: that the wines worth importing, defending commercially, and drinking personally were those produced from cool-climate varieties in regions where elevation, latitude, and Atlantic influence created the acidity and structural tension that distinguished terroir expression from market calculation. That principle was not commercially fashionable during the boom years. It was held by a small number of voices — among them a Berkeley importer documenting the disappearing traditions of French provincial wine culture, whose published convictions ran parallel to and independent of the Spanish argument being made simultaneously by a pioneering Seattle importer from the other side of the Pyrenees. Neither voice was vindicated by the market in the 1990s. Both have been vindicated by the physiological record of those who lived by them.

Happy maturity — physiological stability, mental clarity, the absence of the degenerative patterns the medical literature correctly associates with the

consumption of the wrong product in the wrong manner — is not a claim to immunity from mortality. It is an observable condition, verifiable in the body rather than in a study cohort, accumulated across decades of meal-integrated consumption of the wines described here. No clinical trial runs for fifty years, controls for the quality of what is consumed, and measures not just survival but the texture and composure of a life.[4]

[4] For the structural argument that the necessary stratified clinical study cannot now be run — and why the market transformation itself is the reason — see Part IV, Section 2.

PART II

Epistemic Pluralism and the Wine-Health Debate

This document does not claim that public health authorities are acting in bad faith. It does not claim that epidemiology is wrong. It does not claim that cool-climate dry wine is medicine. It claims only that the wine-health debate is conducted simultaneously in three distinct epistemic registers — policy precaution, epidemiological science, and historical-biocultural continuity — whose governing logics, standards of proof, and authorizing assumptions are rarely made explicit. When they conflict, the conflict is typically misread as a dispute about facts. It is more often a dispute about which kind of knowledge is being asked to do work it was not designed to do.

The preceding Part has argued from within the third register. This Part maps all three.

---

1. Three Registers, Three Governing Logics

The Policy-Precaution Register — exemplified by the U.S. Surgeon General's 2025 advisory on alcohol and cancer — is authorized by a risk-minimization mandate. Its standard of proof is cumulative plausibility under worst-case

assumptions. Its instrument is the population-level warning, designed to reduce aggregate exposure to a classified hazard. It treats product heterogeneity as irrelevant when the asserted mechanism — ethanol metabolized to acetaldehyde — is universal across beverage types. Its silences on confounding variables are not oversights; they are features of a communication instrument optimized for clarity rather than nuance. A causal claim in this register is normative and preventive. Its authority is political-administrative, not epistemically exhaustive.

The register carries a necessary internal limit. Precaution is optimized for action under uncertainty, not for adjudicating the full nature of the object it governs. When provisional judgments are treated as exhaustive descriptions of reality — when the scope of a warning is mistaken for the scope of the evidence — precaution becomes doctrinal. It remains legitimate only insofar as it is transparent about its limits and open to refinement by the registers it does not subsume.

The Epidemiological-Scientific Register — exemplified by the 2026 ACC.26 study of 340,000 UK Biobank participants — is authorized by statistical transparency under controlled assumptions. Its standard of proof is explicit acknowledgment of uncertainty, confounding pathways, and generalizability constraints. It earns credibility precisely by refusing premature causality even when signals are strong. The ACC.26 finding — that moderate wine drinkers showed 21% lower cardiovascular mortality than non-drinkers, while spirits, beer, and cider at equivalent consumption levels were associated with higher mortality — was presented with explicit limitations: observational design, self-reported baseline exposure, cohort selection effects, and lifestyle confounding as a candidate explanation. This register is self-correcting over time. Its structural limit is its dependence on what populations actually consume. When the product category drifts, the evidence accumulated about it drifts with it.[5]

The Historical-Biocultural Register — the register within which Part I operates — is authorized by the convergence of history, chemistry, physiology, and lived outcome. Its standard of proof is biological coherence across time: does the practice sustain the organism that maintains it? It does not reject epidemiology. It bounds its relevance by asking whether the object under study still exists in the form that generated the original signal.

The register has precedents that predate modern epidemiology entirely. Thomas Jefferson provides a useful historical reference point — not as a policy authority,

but as a witness to category differentiation before industrial convergence. Jefferson's well-documented wine purchases and consumption centered overwhelmingly on wines from the traditional winegrowing areas of France and the northern Apennine Peninsula (Piedmont was the "Subalpine Republic" of France from 1802 to 1814) — regions defined by cooler climates, higher natural acidity, and wines produced as meal-integrated foods rather than as concentrated intoxicants. He was not issuing formal medical guidance. But he was reasoning from lived experience about the biological distinction between wine types — arguing, as the letters make clear, that the product mattered as much as the quantity, and that his own body over seven decades constituted the evidence. His relevance lies not in prescription but in continuity: the wines Jefferson drank correspond closely to the same Euro-centric wine styles that dominate consumption in contemporary datasets such as the UK Biobank. When epidemiological studies report outcomes associated with "wine," they are often — by market structure and consumption reality — already weighted toward precisely the cool-climate, drier, lower-alcohol traditions that predate the late twentieth-century transformation of wine into a globalized, technologized commodity. History does not compete with epidemiology here. It contextualizes its exposure variable.

Jefferson's most explicit statement on the subject — written to Jean Guillaume Hyde de Neuville in December 1818 — goes further than cultural observation. "No nation is drunken where wine is cheap; and none sober, where the dearness of wine substitutes ardent spirits as the common beverage." The mechanism he identified was economic and cultural: accessibility shapes consumption, and consumption shapes a society's relationship to alcohol. The 100-point scoring system of the late twentieth century operated by an analogous but more complex logic. The great trophy wines — produced through extreme viticulture, low yields, and late harvesting pushed toward maximum concentration — established a sensory template the scoring system learned to reward. The template proved legible to technology. In warmer climates, commercial intervention could approximate the profile that extreme viticulture had achieved in exceptional sites, at volume and at every price point. The critics, rewarding a sensory profile rather than a place, could not reliably distinguish original from imitation. What resulted was a barbell: trophy wines at one end, industrial approximations at the other, and the ancestral cool-climate product squeezed from the middle — present, often representing genuine value. Jefferson's antidote was not made expensive. It was made harder to find.

Jefferson's own letters confirm that his preference was not merely cultural but sensory and biological. Writing to Thomas Appleton in January 1816, he described Montepulciano as "a very favorite wine," noting that "habit having rendered the light and high flavored wines a necessary of life with me." The phrase is precise: light and high flavored — low in alcohol, high in natural acidity, aromatic through complexity rather than concentration. It is the biochemical profile of cool-climate viticulture described by a man who consumed it daily. The irony of the 100-point scale is that it systematically rewarded the opposite: heavy, extracted, aromatic only in the register of overripeness.

Three years later, writing to Vine Utley in March 1819, Jefferson described his consumption habits with still greater precision: "I double, however, the doctor's glass and a half of wine, and even treble it with a friend; but halve its effect by drinking the weak wines only. The ardent wines I cannot drink, nor do I use ardent spirits in any form." He was not drinking less than his physician recommended. He was drinking differently — and understood that the biological effect was a function of the product, not merely the quantity. The "weak wines" — lower in alcohol, higher in acid, what Part I calls cool-climate dry — allowed him to consume more while experiencing less intoxication. He concluded: "I have been blest with organs of digestion which accept and concoct, without ever murmuring whatever the palate chuses to consign to them, and I have not yet lost a tooth by age." Written at seventy-five, this is the biographical method stated two centuries early. The body kept its own physiological record.

[5] Richard Baxter's Wine and Health (2019), taken in Part III as a representative synthesis of the field, confirms this drift from within the literature itself, documenting the alcohol escalation while continuing to treat "wine" as a stable category.

---

2. The Category Drift Problem

The central methodological contribution of Part I is not a critique of epidemiological method. It is the identification of a prior problem: the object under study changed faster than the evidence accumulated about it.

The shift in global wine production after 1991 was documented in real time by the trade. The 100-point scoring system created demand for a specific style; technology provided the means to supply it. In warm climates that had previously produced only bulk product, refrigeration, acidification, reverse osmosis, and targeted yeast selection allowed producers to transform natural overripeness into structured, scorable wine. The result was the globalization of a product optimized for critic approval rather than meal integration — and the gradual transformation of "wine" as a market category from a fermented food into a recreational intoxicant competing with spirits for consumer attention. This transformation was most pronounced in the United States and in New World producing regions, where the market incentives to conform to critic preferences were strongest and the ancestral constraints of variety and terroir were weakest.[6]

The UK Biobank cohort, by contrast, drew its consumption from a retail supply chain that remained more Euro-centric than the US market — weighted toward European appellations with lower alcohol, lower residual sugar, and higher natural acidity than the global average. The significant presence of Australian wines in the UK market qualifies but does not eliminate this directional bias. The result is that the ACC.26 finding — a 21% cardiovascular mortality advantage for moderate wine drinkers versus non-drinkers — was generated by a cohort consuming wine closer to the ancestral standard than consumers in most other developed markets, and thus showed a positive cardiovascular outcome. That the finding aggregates ancestral and New World styles within a single "wine" variable suggests that a cohort consuming exclusively cool-climate dry wine might show a stronger signal still. The 21% figure is, on this reading, a floor rather than a ceiling.

In epidemiological terms, this is exposure misclassification at the category level — but misclassification that operates differently across markets. When the "wine" variable aggregates ancestral cool-climate dry wine consumed with food and technologically produced high-alcohol off-dry wine consumed without it, the resulting association is an average across heterogeneous exposures. No amount of lifestyle adjustment resolves this, because the confounding is in the product definition itself, not in the cohort characteristics. In the US market, where the post-boom product dominates, the same methodology applied to the same category would likely produce a less favorable or unfavorable result. The UK Biobank's Euro-centric weighting is not a limitation of the Chen study. It is, inadvertently, its most important feature.

The policy register compounds the problem by asserting beverage-type invariance — "regardless of the type of alcohol consumed" — at precisely the moment the epidemiological register is finding that beverage type matters significantly at low and moderate consumption levels. The ACC.26 finding that wine and spirits produce opposite mortality outcomes at equivalent consumption levels directly contradicts the invariance claim. That contradiction has not been addressed in either register.

[6] Baxter's introduction of Enologix Enologix — a firm that reverse-engineers high-scoring wines toward a target chemical profile — provides inadvertent confirmation of the transformation mechanism from within a health-science text; see Part III, Section 4.

---

3. The Living Counterexample

The right wine tradition — cool-climate viticulture, indigenous varieties, minimal intervention, meal integration, the consumption pattern documented across the French Paradox literature and the Mediterranean dietary studies — did not disappear when the market shifted. It contracted. It became the province of producers, importers, and consumers with the knowledge and access to maintain it against the commercial current.

In epidemiological terms, this tradition constitutes the closest available approximation to a controlled study of the ancestral product. Its practitioners are not a cohort anyone has measured. They are a living counterexample to the category-level conclusions being drawn from data that does not distinguish them from the mass market they declined to follow.

That no large cohort study has isolated this tradition as an exposure variable is not a gap in the evidence. It is a consequence of the same market displacement described above. The product capable of testing the hypothesis has become too scarce, too access-dependent, and too unevenly distributed across retail supply chains to appear in population-level data at measurable concentration. The absence of corroboration does not count against the argument. It is part of the argument.[7]

Part I is, among other things, a fifty-year longitudinal record of one such practitioner. Its biographical evidence is not scalable. It is not peer-reviewed. It does not meet the evidentiary standards of either the policy or the epidemiological register. What it offers instead is what those registers structurally cannot provide: a first-person account of biological coherence maintained across a specific practice, over a specific duration, with a specific product. The body kept its own physiological record. The archive keeps its timestamp.

Epistemic pluralism does not resolve the conflict between these registers by declaring a winner. It resolves it by making explicit what each register can and cannot see — and by insisting that the object none of them has yet adequately measured continues to exist.

[7] For the full structural argument that the absence of stratified clinical evidence reflects a methodological constraint rather than an evidentiary gap, see Part IV, Section 2.

The preceding Parts have established the epistemic structure within which the wine-health debate operates: the three registers that govern it, the product instability that the epidemiological-scientific register cannot detect, and the category drift that has made "wine" an unreliable referent in the literature that continues to use it. What follows asks whether the field itself — in its most careful and representative form — contains the resources to answer the question it has not asked. The answer is that it does. The question is why it has not asked it.

PART III

Wine & Health: An Epistemic Perspective

Richard Baxter's *Wine and Health: Making Sense of the New Science and What It Means for Wine Lovers* (2019) represents a careful, balanced, and self-critical synthesis of the wine-health literature by a physician with no commercial stake in the wine industry. It is taken here as a reliable map of the field's current state — its

established findings, its acknowledged uncertainties, and, crucially, the questions it has not asked. The purpose of this Part is not to dispute that map but to examine its boundaries.

The perspective brought to bear draws on the framework developed in Parts I and II — the trade-professional record of the transformation and the three-register analytical structure — and applies both to the mainstream scientific literature as Baxter represents it. The question is whether that literature, read carefully, already contains the resources to pose the question it has not asked. The answer, as the following sections demonstrate, is that it does.

---

1. The Field as Baxter Represents It

The modern scientific interest in wine and health can be dated with unusual precision. A 1979 article in *The Lancet* by St. Leger, Cochrane, and Moore of Cardiff reported that heart disease mortality correlated inversely with wine consumption across developed nations. The authors had no explanation for the finding, but noted with characteristic understatement that if wine were ever found to contain a constituent protective against ischemic heart disease, isolating that constituent from its source would be something close to a sacrilege. The medicine, they suggested, was already in a highly palatable form.

What followed was an expanding field of inquiry touching cardiology, neurology, oncology, epidemiology, and biochemistry. The French Paradox — French populations consuming relatively high levels of saturated fat yet showing low rates of cardiovascular disease, with wine consumption as a defining feature of their lifestyle — became a household term after a 1991 television broadcast and generated a wave of research that has not fully subsided. Baxter traces this arc with clarity and appropriate skepticism: the inflation and deflation of resveratrol as a unifying explanation, the mounting evidence that wine's benefits are not reducible to any single compound, and the pendulum swing toward neo-prohibitionism that has increasingly characterized public health policy.

The Cretan data that preceded the French Paradox by three decades deserves particular note. Ancel Keys' *Seven Countries* study, published in the 1950s, found that residents of Crete enjoyed the longest life expectancy among the populations

studied despite poor access to healthcare, with cardiovascular mortality at roughly 10% of the American rate. They were also heavy smokers with a relatively high fat intake. Wine with meals was a defining feature of the lifestyle. Baxter calls this the "Cretan Conundrum" — a paradox presaging the French Paradox by a generation, and one that eliminates the "better medical management" counter-argument entirely. These people were healthy without medical intervention.

Against this background Baxter proposes what he calls the skeptic's checklist: the criteria a hypothesis must satisfy before it can be considered established. Is there epidemiological evidence — population surveys showing a correlation? Do studies of different types reach the same conclusion? Is there a plausible cause-and-effect explanation? Is there clinical evidence of measurable benefit? Wine, he concludes, satisfies all four. It is this checklist, and the body of evidence Baxter marshals to satisfy it, that this Part takes as its point of departure.

That candor, examined in detail, is precisely what makes Baxter's synthesis useful here. His willingness to note the limitations of his own evidence, to criticize the resveratrol narrative from within, and to acknowledge the alcohol escalation problem without defensiveness sets him apart from much of the popular literature on the subject. The analysis that follows is not a dispute with his findings. It is an examination of the frame within which those findings have been made, and of the question that frame has consistently left outside its boundaries.

---

2. What the Science Established and When

The founding epidemiological signal was detected in specific populations at a specific historical moment. The residents of Crete in the 1950s, the French cohorts of the 1970s and 1980s, the Danish populations whose grocery purchasing patterns across 3.5 million supermarket transactions were analyzed by Morten Grønbaek's team — these were populations consuming a product with identifiable characteristics. It was European in origin, produced in cool or moderate climates from varieties long adapted to those conditions, made by traditional methods with minimal technological intervention, and consumed at alcohol levels of 12 to 13 percent as a regular accompaniment to meals.

Baxter himself documents what happened next. A 2015 study from the University of California Davis, published in the *Journal of Wine Economics*, found a documented trend toward rising alcohol levels across both Old and New World wines, correlating with sites of greatest average temperature increase. Traditional wines, Baxter notes, had alcohol contents of around 12 to 13 percent; it is now not unusual to see wines above 16 percent. He observes that health studies are generally based on the presumption of the lower alcohol levels, and that calibrating consumption of modern wines accordingly is "a bit like taking credit for eating your vegetables even though they are deep fried."

The analogy is his own, and it is precise. But it frames the problem as one of individual calibration rather than systemic product transformation. The question it implies but does not ask is whether the deep-frying happened to the entire category, and whether the studies that established the health benefit were studying a product that the market has substantially replaced. This is not a question about individual consumer behavior. It is a question about the referent of the literature — about what "wine" denotes in the epidemiological record versus what it denotes on the shelf of a contemporary retailer.

The product-substitution problem does not invalidate the science. It recontextualizes it. The signal is real; the mechanism is established; the population studies are valid for the product they studied. What has not been established is that the product they studied is the product currently available at scale to the populations whose health is now at issue.

---

3. The Mechanism the Field Identified

Baxter's Chapter 5 provides the biochemical account of why wine produces the effects the epidemiological record documents. It is worth following in some detail, because the mechanism is product-specific in ways the field has not fully acknowledged.

The central molecules are polyphenols — a large family of compounds that includes flavonoids, tannins, resveratrol, and numerous related structures. Polyphenols are produced by the grapevine as a stress response: to ultraviolet radiation, fungal challenge, bacterial pressure, and the general metabolic demands

of ripening under difficult conditions. The vine stressed by poor soil, limited water, and climatic challenge concentrates polyphenols in the grape skin. The vine grown in fertile soil with irrigation and optimized nutrition produces fruit efficiently but with a diminished polyphenol profile. This relationship — vine stress to polyphenol concentration — is the biochemical foundation of the health argument, and it is a direct function of where and how the grape is grown.

The health consequences of this polyphenol load are extensive. Polyphenols bind LDL cholesterol and reduce its oxidation, the process most directly implicated in arterial plaque formation. They inhibit *Helicobacter pylori* and its toxins — the bacterium now known to be responsible for the majority of peptic ulcers, a finding that retrospectively vindicates the traditional European practice of wine as an *aperitif* and *digestif*. They exhibit antiviral activity by binding surface proteins that viruses use to penetrate host cells. They inhibit the enzyme that facilitates dental plaque formation. They have been shown to minimize the postprandial rise in oxidized LDL when consumed with meals — the "postprandial oxidative stress" that Baxter identifies as one of the primary mechanisms by which diet accelerates aging.

Complicating this picture, Baxter notes, is a commercial pressure that works directly against the polyphenol-concentration mechanism. Wine critics and consumers have increasingly demanded concentrated, intense flavors — a profile achieved by delaying harvest past the point of physiological ripeness to accumulate sugars and intensify phenolic extraction. The result is higher alcohol, a different phenolic profile, and a product whose relationship to the studied mechanism is at best uncertain. Baxter registers this tension at the level of individual viticulture. He does not extend it to the market as a whole.

---

4. The Template Legible to Technology

Chapter 5 of Baxter's book opens with a description of Enologix, a Napa Valley firm that reverse-engineers high-scoring wines and advises producers on manipulating vineyard management and winemaking processes to match a target chemical profile. Baxter presents this without critical comment, as a notable technological development. It is taken here as something more: the field's

inadvertent acknowledgment, from within a health-science text, that the wine product is fully manipulable toward a commercially determined target.

The target Enologix optimizes for is the critic-score profile. That profile — concentrated, extracted, high in alcohol, designed for immediate sensory impact — is not the profile of the wines whose consumption produced the founding health signal. The stressed-vine polyphenol matrix that Baxter's biochemistry identifies as the active mechanism is not what Enologix is engineering toward. The two optimization targets are different, and the market has been organized around one of them for three decades.

This is not a criticism of Enologix or of the producers who use its services. It is an observation about what the market has selected for and what the health literature has continued to assume. The template that proved legible to technology was the flavor profile of a specific wine type; the health benefit associated with wine in the literature derived from a different profile, produced by different means, under different conditions. The field has not registered the divergence.

---

5. The Asymmetry Baxter Exemplifies

Running through Baxter's synthesis is a consistent asymmetry that is worth naming directly, because it characterizes the field as a whole and not merely one author's choices.

Baxter observes that the processed food products available today "bear little resemblance to traditional fare," and that habits of eating and drinking have been shaped by cultural and religious practice for as long as there have been human societies. He does not apply the parallel observation to wine. He documents the alcohol escalation and frames it as a consumer-calibration problem. He establishes the stressed-vine / polyphenol relationship and frames it as a price-quality correlation. He proposes a "Drinking 101" curriculum that would teach how to drink — with meals, in moderation, as a regular practice rather than an occasional excess — but not what to drink beyond the general category of wine. At each point the argument approaches the product-transformation question and turns away from it.

The asymmetry is not an intellectual failure. Baxter is a careful thinker and his candor about the field's uncertainties is genuine. The asymmetry is structural. The medical and professional community most capable of recognizing and articulating the product-transformation argument is the community most socially embedded in the post-transformation industry. A physician whose wine experience is formed within a community that drinks well — Euro-centric, top-tier, with the economic means to access the product that actually delivers the mechanism — has no personal experience of the problem. And a physician whose professional social world intersects with a local wine industry built on the post-transformation model has reasons, none of them cynical, to frame the issue as one of individual calibration rather than categorical product failure.

The silence, in other words, has a social geography. It is not the silence of ignorance but the silence of embeddedness. Naming it is not an accusation. It is an observation about why a framework developed outside that embeddedness — from the vantage point of a trade professional who watched the transformation occur and has the analytical record to document it — is necessary to ask the question the literature has left unasked.

---

6. The Affordability Refutation

The field's implicit assumption — shared by Baxter's "Eyes on the Price" sidebar — is that the health-relevant product is expensive and therefore impractical as a public health recommendation. The current generational rejection of wine has produced an industry-wide crisis that directly refutes this assumption. Market contraction has created buying opportunities in traditionally produced wines at prices that would have been unimaginable during the premium expansion of the 1990s and 2000s. The wines that never entered the technological transformation pipeline are available in a stressed market at prices that make the affordability objection untenable. The barrier to accessing the right product is informational, not economic.

The qualification is that appellation alone is insufficient as a guide. The transformation was not geographically bounded but profile-driven, following a specific flavor target — concentrated, high-alcohol, critic-score optimized — across borders and traditions wherever the local raw material proved adaptable to

it. In Spain, Ribera del Duero — source of some of the founding expressions of traditional Castilian winemaking — now warrants the description "Napa del Duero." Toro and Jumilla followed the same arc. In Italy, the wines of Puglia and Abruzzo tell a recognizable story. The transformation followed the flavor profile, not the flag. Within producing areas the variation can be as significant as between them, and the consumer requires the epistemic tools to discriminate at that level — which is precisely what Part I provides.

The generational rejection of wine that has driven the current market crisis deserves a brief hypothesis of its own, because its consequences for the argument are not straightforward. The most visible driver is the broad cultural demonization of alcohol as a category — a policy-precaution register response that makes no distinction between wine consumed with meals as a dietary practice and spirits consumed for intoxication. The baby has been discarded with the bathwater. But it is at least worth asking whether the dominant product of the post-transformation era contributed to its own rejection. A wine optimized for critic scores and cellar aging, consumed at ambient room temperature rather than the cool cellar temperature at which its character is properly expressed, delivers an experience of heat, weight, and alcoholic intensity that bears little resemblance to the wine-with-meals practice the health literature documents. The demonization of alcohol per se and the deterioration of the dominant product are not mutually exclusive explanations. Both may have contributed to a rejection that has caught the traditionally produced wines least responsible for either problem in its wake.

---

7. Pre-Theoretical Confirmation

Two instances of pattern recognition, preceding and independent of the scientific literature, converge on the same product-specific mechanism that Baxter's biochemistry confirms. They are noted here not as anecdotal evidence in the dismissive sense Baxter rightly cautions against, but as instances of independent confirmation — the criterion his own checklist identifies as essential to establishing a hypothesis.

Thomas Jefferson's documented wine-with-meals practice and longevity are examined in detail in Part II, Section 1, where his letters establish that the biological effect he observed was a function of the product — the "weak wines,"

lower in alcohol, higher in acid — not merely the quantity. That Baxter independently cites the same Jefferson letter that appears as a primary source in Part II is itself a form of confirmation: two texts, arriving at the same primary source from different directions, converging on the same product-specific argument.[8]

Alejandro Fernández, founder of Bodegas Pesquera in Ribera del Duero, was an instinctual winemaker without formal training who produced wines more tannic than his neighbors' in the early period of the appellation's recognition. When asked to account for the difference he offered a simple explanation: his wines cured his ulcers. He was 101% confident in their health benefits — "the wine of no headaches" was his characterization of what he produced. The observation predated the identification of *Helicobacter pylori* as the primary cause of peptic ulcer disease — a discovery that would eventually earn its authors a Nobel Prize — and has since been confirmed by the protein-binding mechanism Baxter documents in detail. Higher polyphenol load, greater inhibition of the bacterium and its toxins: the folk pharmacology and the molecular biology describe the same event. The checklist criterion of independent confirmation is satisfied by a winemaker who had never heard of a checklist.

It is noted that the appellation Fernández helped establish has since followed the broader transformation arc. The founding-period product that gave rise to the observation is not representative of what Ribera del Duero produces at scale today.

[8] For the full Jefferson treatment including specific letter citations, see Part II, Section 1.

---

8. The Color Question

The foregoing argument has been conducted primarily in the register of red wine, reflecting the literature’s own emphasis on polyphenols and the French Paradox signal. This emphasis should not be read as exclusion. Part I established the health-relevant product through its production characteristics — low residual sugar, low pH, minimal intervention, meal integration, moderate alcohol — and those characteristics describe a tradition that has always included white wine. The UK Biobank data, stratified by color, shows comparable inverse associations between

white wine and champagne consumption and waist circumference as between red wine and the same measure, for both sexes. The meal-integration variable the ACC.26 team identifies as a candidate explanation for wine's cardiovascular advantage over beer and spirits makes no color distinction. The higher natural acidity of cool-climate dry whites, their characteristically lower alcohol, and their particular compatibility with food make them in some respects the most reliable expression of the ancestral model — wines that by their nature invite integration rather than isolation.

Mario Soldati, encountering Bruno Giacosa's 1974 Arneis in Neive at 12% alcohol, wrote that its advantage was precisely this: you can drink more of it and drink it more often. That is not a concession about potency. It is a precise statement about integration — the wine that belongs at the table every day, that never tires, that accompanies rather than overwhelms.

A parallel instance exists in Ángel Rodríguez and his Martínsancho Verdejo in Rueda. In his quiet and proud way, Ángel was as historically significant for Spain's white wines as Alejandro Fernández was for reds — his temperamental opposite, his equal in conviction. Where Fernández was expansive, Rodríguez was reserved; where Fernández spoke of his wines curing ulcers, Rodríguez expressed his convictions through the vine itself.

By the 1970s, the Verdejo grape was effectively extinct commercially — destroyed first by phylloxera, then by the Depression, then by Franco's agricultural policies, which subsidized permanent crops and bulk varieties at the expense of Rueda's indigenous white. Rodríguez ignored the revisionist thinking and preserved a single hectare of ancient Verdejo vines on their own ungrafted roots. In 1972 he planted a new 25-acre vineyard from cuttings taken from this living conservatory, trained in the traditional goblet form — en vaso — dry farmed, at extremely low yields. When those vines reached maturity, Martínsancho was born — produced from 1982 onward in neutral tanks, a simple and direct expression of the grape, making no attempt to impose style on what the old vine material provided. The pre-commercial production from the ungrafted conservatory had been sold in bulk; the bottled wine the world came to know was the first-generation descendant of that act of preservation. Emile Peynaud had arrived at the same conclusion independently: hired by Marqués de Riscal to identify a white wine counterpart to their celebrated Rioja reds, he scoured Spain, came across Ángel and his old vines,

and rendered his verdict — Verdejo was the true jewel of Spain's white varieties. The wine Peynaud identified was Ángel's. For his efforts, Rodríguez received the Cruz de la Orden Civil del Mérito Agrícola by Royal Decree of Juan Carlos I.

The numbers confirm what the palate established. The 2021 vintage analysis shows 13.1% alcohol, a pH of 3.16, and residual sugar below 1.9 g/L — biological stability achieved through natural acidity rather than chemical intervention. Martínsancho is not a light wine; its density comes from old vines rather than technological extraction. What it shares with Giacosa's Arneis is the quality Soldati identified: it never tires. The pH explains why. The dryness explains why. The moderate alcohol explains why. These are not incidental characteristics — they are the same characteristics that define the health-relevant product throughout this work, expressed in white. Ángel's daughter and son-in-law have maintained total fidelity to that profile. The wine continues as it was.

The research field's polyphenol focus has narrowed the conversation in ways the evidence does not require. Authentic Champagne, Grüner Veltliner, Arneis, Verdejo, Albariño, Muscadet, Vermentino — these are expressions of the same production philosophy as a cool-climate Tempranillo or a traditionally made Pinot Noir. The barrier to including them is not scientific. It is the same category drift that has made "wine" an unreliable referent throughout: a literature organized around red wine's measurable compounds has left the broader tradition incompletely described. The criterion this work applies — refreshing, never tiring, a beverage integrated into the meal rather than consumed apart from it — is color-blind. It always was.

PART IV

The Structural Conclusion

---

1. The Wrong Product Hypothesis

The wine-health literature has established the signal, identified the mechanism, and documented the product transformation. In each case the evidence is available

within Baxter's own synthesis. What the literature has not done is connect these three findings into the question they jointly imply: whether the product now dominant in the market delivers the mechanism that produced the signal. This is not a failure of science. It is a failure of epistemic framing — a consequence of operating within a single register when the question requires three.

Baxter's skeptic's checklist, applied to the "wrong product" hypothesis, returns a positive result on its own terms. The epidemiological correlation exists and predates the French Paradox by a generation. Independent confirmation is available across study types, across populations, and — as the cases of Jefferson and Fernández illustrate — across the boundary between scientific and pre-theoretical knowledge. The cause-and-effect mechanism is established in Baxter's own biochemical account, and it is product-specific. The absence of clinical studies stratifying explicitly by production method and climate is not a refutation of the hypothesis but the precise gap it identifies — the question that has not been asked within the register in which it needs to be asked.

There is, however, one finding that merits reexamination in this light. The ACC.26 study of 340,000 UK Biobank participants is conventionally treated as an unstratified result — a finding about wine as a category, subject to all the product heterogeneity the wrong product hypothesis identifies. It is more precise than that. The UK retail supply chain from which the cohort drew its consumption was, and remains, weighted toward European appellations with lower alcohol, lower residual sugar, and higher natural acidity than the global average. That weighting is not a limitation of the Chen study. It is, inadvertently, a partial stratification — not by design, but by market geography. A cohort consuming wine closer to the ancestral standard than consumers in any other major developed market showed a 21% cardiovascular mortality advantage over non-drinkers, while spirits, beer, and cider at equivalent consumption levels were associated with higher mortality. This is not the stratified study the wrong product hypothesis requires. But it is the closest thing to one that current market conditions permit. And it points in exactly the direction the hypothesis predicts. The 21% figure is, on this reading, a floor rather than a ceiling — the signal produced by a cohort already weighted toward the right product, within a single variable that still aggregates ancestral and post-transformation wines. A cohort consuming exclusively the product defended here would, on the logic of the hypothesis, show a stronger signal still. The necessary

study cannot be run by design. It has been partially run by accident. The result is positive.

The three-register framework developed in Part II provides the structure within which the question can be posed and the existing evidence recruited toward an answer. Part I provides the practical specification of the product that answer identifies. The present Part connects them into the structural argument the literature has not drawn.

---

2. Why the Necessary Study Cannot Be Run

The absence of stratified clinical trials does not reflect a failure of scientific will or resources. It reflects a methodological constraint imposed by the market transformation itself. The exposure capable of settling the question at scale — a population consuming the historically health-relevant product as a regular dietary staple, distinguishable from a parallel population consuming the post-transformation product — no longer exists in sufficient concentration within contemporary retail systems to support a clean, population-scale clinical cohort. The transformation that displaced the product has also eliminated the conditions under which its effects could be isolated and measured against a contemporary control.

This is not an argument for abandoning the question. It is an argument for recognizing what kind of question it is: a structural and historical question that requires the three-register framework to pose, and that the epidemiological-scientific register alone — for methodological reasons that are now irreversible at the population level — cannot answer.

---

3. The Wine that Remains

The wine that produced the signal is still available. It is not expensive. It requires only the knowledge to find it.

These wines continue to exist for the same reason they always have: because the cultures that produced them never stopped producing them. Wine as a part of daily

life, integrated into cuisine and social rhythm, does not require a premium market to sustain it. The current industry contraction has made traditionally produced wines more accessible than at any point during the boom years — but availability was never contingent on market conditions. It was always contingent on cultural continuity, and that continuity has proved more durable than the transformation that temporarily obscured it.

The wines that never entered the technological transformation pipeline are not confined to any single geography. The Old World model has its practitioners in the New World; the transformation has its footprint in traditional producing areas. What identifies the right product is not an address but a production philosophy — the same philosophy that made Tannat the wine of Madiran's farmers and the biochemical explanation for what Alejandro Fernández observed in his own cellar.

The barrier to accessing this product is informational, not economic. The framework this work provides is the instrument for navigating it.

Coda: Wine as Food, Once and Still

Oliver Wendell Holmes closes Baxter's epilogue: *When wine enlivens the heart, may friendship surround the table.* The table, the meal, the friend, the specific glass — these are not decorative additions to a biochemical argument. They are the argument. The field has been circling them for forty years.

Appendices

A. On the Charge of Anecdotalism

This work does not substitute biography, tradition, or individual experience for scientific evidence. Epidemiological associations, biochemical mechanisms, and large-scale observational studies provide the backbone of the argument, primarily as synthesized in Richard Baxter's *Wine and Health*. Historical and biographical instances — such as Thomas Jefferson's documented consumption habits or Alejandro Fernández's pre-theoretical observation regarding ulcer healing — are introduced only where they satisfy the scientific criterion of independent confirmation.

These cases are not offered as proof, nor as generalizable prescriptions. They are cited because they precede the scientific literature, align with mechanisms later established within it, and arise independently of one another. Their role is diagnostic: to show that the proposed product-specific hypothesis coheres across domains that did not inform one another. They supplement, rather than replace, the scientific record.

B. On Public Health Scalability

This work does not propose changes to public health policy, nor does it argue that population-level guidance should be based on non-scalable or access-dependent knowledge. The policy-precaution register is recognized as legitimate within its mandate to minimize harm under uncertainty.

The argument made here is structural rather than prescriptive. It observes that the market forces which transformed the wine category since the early 1990s have also eliminated the possibility of isolating the historically health-relevant product

within contemporary population cohorts. As a result, the absence of stratified clinical trials reflects a methodological constraint, not an evidentiary failure.

The purpose of identifying this constraint is not to demand policy action, but to prevent category error: treating conclusions drawn about one product as though they necessarily apply to another. Public health guidance may properly remain cautious at the category level, but scientific clarity requires recognizing when categories no longer correspond to the objects that generated the original evidence.

Released under CC0 1.0 Universal (Public Domain)

The three essays from which this unified work is drawn are available individually at Internet Archive under the pen name Trade Veteran.